Advances in the treatment of ocular dryness associated with Sjögren׳s syndrome. by Ciurtin, C et al.
Advances in the treatment of ocular dryness associated with Sjögren’s syndrome 
 
 
 
Coziana Ciurtin¹, Anca Ostas², Viorica M. Cojocaru³, Stephen B. Walsh4, 
David A. Isenberg¹, 
 
 
¹Department of Rheumatology, University College London Hospital, 3rd Floor Central, 250 
Euston Road, London, NW1 2PG, UK 
²Division of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes Street, 
400012 Cluj-Napoca, Romania 
³Department of Ophthalmology, L'Hôpital Schweitzer, 201 Avenue d'Alsace 68003, Colmar, 
France 
4Division of Medicine, Royal Free Hospital, University College London Hospitals NHS Trust, 
Pond St, London NW3 2QG, UK 
 
 
 
 
CORRESPONDENCE TO: 
Dr. Coziana Ciurtin, University College London, 3rd Floor Central, 250 Euston Road, London, 
NW1 2PG. email: c.ciurtin@ucl.ac.uk. 
 
 
 
The authors declared no conflict of interests.  No grant or industry support was received for 
this study. 
 
Introduction: 
SS is a common autoimmune rheumatic condition, associated with localised symptoms of 
ocular and mouth dryness as a consequence of decreased lacrimal and salivary secretion 
due to the lymphocyte infiltration of the exocrine glands (1, 2).  The incidence of pSS varies 
among different populations and depends on the classification criteria used for diagnosis (3, 
4). A recent meta-analysis showed an incidence of 6.92 (95% CI 4.98 to 8.86) per 100 000 
person-years and overall prevalence of  60.82 (95% CI 43.69 to 77.94) cases per 100 000 (5). 
The pathogenesis of dry eye symptoms associated with SS remains uncertain (6, 7); lacrimal 
gland infiltration with B and T lymphocytes and epithelial cells activation driven by cytotoxic 
T cells, together with increased apoptosis, and expression of Ro and La antibodies on the 
surface of apoptotic cells are considered to be the main pathogenic events associated with 
glandular destruction in SS (8). More recently, it was found that abnormal apoptosis, 
cytokine and toll-like receptor (TLR) activation and perivascular lymphocytic infiltration are 
present in the glandular tissue even before the onset of clinical symptoms associated with 
SS (9). In contrast, the systemic features of SS seem to be more associated with B cell 
activation, autoantibody production and polyclonal hypergammaglobulinaemia, which is 
likely to be linked to the increased risk of lymphoma observed in these patients (10, 11).  
Despite the recent efforts of ophthalmologists to define and classify the dry eye disease 
(12), very few publications have critically reviewed the evidence for treatment 
recommendations (13). 
The ocular dryness is always associated with a localised inflammatory process and damage 
of the ocular surface, which is common to all underlying conditions (14).   Although often 
labelled as a benign feature of SS, the eye dryness can lead to decreased quality of life and 
potentially severe complications (15). A recent study found no correlation between the 
perceived sicca symptoms and the tear secretion in pSS patients, despite good correlation 
with age and disease activity (16). The incidence of dry eye is increased in the older 
population (17) and also after cataract and refractive surgery (18). Symptoms of ocular 
dryness are reported with different frequency by patients with rheumatic conditions (19, 
20).  
Methods: 
We search PubMed (MEDLINE) and EMBASE electronic data bases from January 1994 to 
September 2014, aiming to identify reports about different therapies for dry ocular 
symptoms associated with SS, using the following MeSH terms: Sjogren’s syndrome 
treatment, dry eye treatment, sicca syndrome and keratoconjunctivitis sicca treatment. 
Using all these terms combined, we identified 458 articles. Only the articles in English, 
reporting on data about the effectiveness of treatment in SS were included in the review 
(n=163). We excluded case reports and animal model studies, and complemented the 
electronic search by a hand research of the references of the review articles related to this 
topic. Ultimately, 78 relevant articles were carefully reviewed.  
 
Therapeutic strategies 
 
The current therapeutic armamentarium comprises artificial tears, topical applications of 
immunosuppressant therapies, systemic immunosuppressant and immunomodulatory 
therapies, secretagogues and interventional treatments. We summarise below the main 
treatment options currently available for addressing of symptoms of dry eye associated with 
SS (Table 1).  
 
 
Topical treatments 
 
It is currently recognised that the ocular dryness is associated with a local inflammatory 
process. The efficacy of topical antiinflamatories was tested in two randomised controlled 
trials (RCT), one prospective, open label, using diclofenac 0.1% drops (21) and one 
controlled, parallel group study, comparing diclofenac 0.1% with indomethacin 0.1 % eye 
drops (22). Both studies showed improvement of the subjective symptoms in the NSAIDs 
treatment arms, which was not maintained at day 28 in the first study, and was associated 
with significant worsening of the corneal staining in the diclofenac group in the second 
study. It is currently accepted that topical NSAIDs should be used with caution in patients 
with SS (22) (Table 1). 
 
The use of topical corticosteroids was effective in one prospective trial of 53 SS patients, 
which used methylprednisolone, initially administered 4 times daily for the first two weeks, 
and tapered every 2 weeks. The treatment led to significantly improved tear break-up time 
(BUT) and Schirmer test results at the end of the treatment period and drug-free remission 
for a mean duration of 56.6 weeks and 20.8% recurrences. The clinical improvement was 
associated with an increased number of conjunctival goblet cells as assessed by impression 
cytology (23).  
 
The use of topical applications with artificial tears was associated with statistically 
significant changes in contrast sensitivity over a 4 hour period of instillation of a variety of 
artificial tears in patients with SS in a randomised controlled trial (RCT). It was also observed 
that the more muco-adhesive artificial tears demonstrated a significantly greater effect (24).   
Both artificial tears and punctal plugs relieved dry eye symptoms, repaired corneal lesions, 
enhanced tear film stability, and improved contrast sensitivity in patients with pSS (25). 
Instillations with 0.4% sodium hyaluronate were effective in achieving improvement in the 
rose bengal conjunctival stain starting from day 15 (p = 0.01) and for BUT and fluorescein 
corneal stain at day 90, but showed no improvement in the Schirmer’s test, according to 
another RCT involving patients with primary (pSS) and secondary SS (26).  
Autologous serum (20%) topical applications were also associated with improvement in the 
Rose Bengal and fluorescein scores (p<0.01 and p<0.05, respectively) after 4 weeks (27). 
However, no significant change in BUT scores was observed, despite the improvement in the 
dryness sensation, as reported by 12 patients with pSS treated for 4 weeks.  In another 
study, including 3 different groups of patients with ocular symptoms, autologous serum 
(concentration 100%) was associated with the best outcome in improving the sensation of 
dryness (p<0.01) and decrease of the corneal staining score in the SS group (p=0.041) after 
12 weeks (28).  
Several clinical trials investigated the efficacy of cyclosporine 0.05%, topical application, in 
patients with SS and dry eye symptoms (29-31). In a 24 week RCT using two different doses, 
0.5% and 1 %, there was evidence of improvement in several dry eye-related outcomes 
(Table 1); (32). Cyclosporine 0.05% was as effective as vitamin A (ocular instillations), and 
superior to carbomethylcellulose, in improving the symptoms of blurred vision and break 
time and Schirmer tests (p=0.05) (Table 1)(33). 
Cyclosporine topical applications improved both, the mean corneal fluorescein staining 
scores (p ≤ 0.001) and global physician assessment of dry eye status (in 72.7% SS patients) in 
a prospective study (31).  
 
Oral treatments: 
Several oral treatments were used to assess their efficacy in controlling different symptoms 
associated with SS. Pilocarpine is a non-selective muscarinic acetylcholine receptor M3 
agonist, known to stimulate the secretion of saliva and sweat, as established many years 
ago (34).  
In a recent RCT, comparing the efficacy of pilocarpine 5 mg twice a day (n=29) with artificial 
tears (n=28) and inferior puncta occlusion (n=28), pilocarpine significantly improved the 
subjective global assessment of dry eyes compared with artificial tears (p<0.001) and 
inferior puncta occlusion (p<0.05). Furthermore, patients receiving oral pilocarpine also 
showed greater objective improvement, as measured by the Rose Bengal test (p<0.05), 
although the Schirmer test showed no differences between the treated groups (35). 
Another large RCT, placebo controlled, assessed the efficacy of pilocarpine 20-30 mg daily 
(dose adjustment study) vs. placebo in patients with SS. The pilocarpine group 
demonstrated both significant improvement in global assessment of dry eyes related 
symptoms (p 0.0001) and relief in 6 of 8 dry-related symptoms as assessed using a patient 
questionnaire (p≤0.04) at 12 weeks (30 mg/daily) (36). 
In another RCT, pilocarpine 5 mg, four times daily, was effective in improving the symptoms 
associated with dry mouth and dry eye (61% vs, 31%, p<0.001 and 42% vs. 26%, p=0.009) in  
comparison with placebo (37). The efficacy of cevimeline was confirmed in a prospective, 
double-blinded trial which followed up pSS patients for 4 weeks (20 mg t.d.s.) and in a 12 
week RCT (30 mg t.d.s), which both showed statistically significant improvements in patient 
subjective global assessment of dry eyes and lacrimal flow rates, as measured by Schirmer's 
test (38, 39). 
 
Hydroxychloroquine (HCQ) has been used in SS and found beneficial in controlling the 
symptoms of oral dryness and joint pain associated with SS (40). 
The efficacy of HCQ in controlling symptoms of dry eye was confirmed in pSS patients in a 
prospective study where patients were assessed 3 months after stopping HCQ. However, a 
significant worsening was observed in, tear break up-time (TBUT) (P < 0.001), lissamine 
green (p < 0.01) and corneal fluorescein staining scores (p < 0.003). Improvement of 
subjective symptoms was also noted after 12 weeks treatment with HCQ (P < 0.007 and P < 
0.003, respectively) (41).  A clinical improvement in the symptoms of ocular dryness was 
associated with decrease in the tear BAFF levels (41). However, a recent RCT study showed 
no efficacy of HCQ in controlling the symptoms of dryness associated with SS after 24 weeks 
of treatment (42). 
Methotrexate did not improve objective features of ocular dryness, despite being effective 
in improving the reported symptoms of dryness, as assessed by an open, one-year pilot 
study with weekly methotrexate (43). A small open-label study with leflunomide 20 mg 
daily, including 15 patients with pSS with early and active disease, found no statistical 
significant difference in terms of perceived ocular dryness of objective improvement in the 
Schirmer test (44). No significant improvement of the ocular dryness was reported in studies 
with azathioprine (45) or oral cyclosporine (46), and the use of thalidomide was associated 
with prominent side-effects (47). 
Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, was reported to be effective in 
increasing  the secretion of both membrane-associated and secreted-type mucins through 
mucin production in the conjunctival goblet cells, and in the corneal epithelial cells (48). This 
mucin secretagogue, used as ocular suspension was more effective than sodium 
hyaluronate at relieving the symptoms of ocular dryness and improving the corneal and 
conjunctival staining tests in a RCT in 188 patients with dry eye (49). There are no studies 
available to assess its efficacy in patients with SS.  
A large recent 6-week RCT, placebo controlled study, including 240 patients with SS and 
testing a Chinese traditional herbal medicine compound (granules) showed a significant 
improvement in the Schirmer test in both eyes, and also in the salivary flow, in the 
treatment arm compared with placebo (50).  
The treatment of end-stage autoimmune dry eye associated disease with MICOF 
keratoprosthesis is considered to be one of the last resorts in the therapeutic 
armamentarium. Studies reported variable rates of success and additional treatment, 
comprising prophylactic autologous auricular cartilage implantation aiming to reinforce the 
anterior surface of recipient’s cornea was needed to preserve the ocular integrity following 
corneal melting (51). Despite the increasing experience with corneal transplants, there are 
no reports of this treatment being effective in the end-stage ocular disease associated with 
SS, suggesting that this condition is reasonably well controlled with conservative treatment. 
Table 1: Treatments for ocular dryness associated with SS 
 
Authors Study design/patient characteristics/ 
medication dose 
Main results 
 
Topical NSAIDs 
Aragona et al, 
2004 (22) . 
Controlled, single-blind, parallel, clinical 
study, 20 patients (8 with pSS and 12 with 
sSS),  0.1% indomethacin vs. 0.1 % 
diclofenac; 30 day study with a follow-up 
visit 7 days after the discontinuation of 
therapy. 
Both groups showed at day 30 a statistically 
significant reduction of corneal sensitivity 
(p<0.05). 
The ocular discomfort score was statistically 
significantly reduced in both groups starting 
from day 15 (p<0.05). 
Zhang et al, 
2013 (24). 
10 SS patients were assessed over a 4-
hour period after instillation of a variety of 
artificial tears.   
Statistically significant changes in contrast 
sensitivity were measured over time after 
artificial tear instillation, with the greatest effect 
at 3 to 6 cycles.  
Artificial tears and autologous serum 
Tsubota et al, 
1999 (27). 
Case-control clinical trial, n= 12 patients 
with SS were treated with autologous 
Subjective comfort evaluated using a 
questionnaire improved significantly at 2 and 4 
serum 20%, for 4 weeks. weeks, respectively (p<0.05).  
   
Cho et al, 2013 
(28). 
Patients with SS, dry eye, and persistent 
epithelial defects were randomly treated 
with autologous serum eye drops for 12 
weeks at different concentrations: 100% 
(AS100), 50% serum with normal saline, 
sodium hyaluronate or ceftazidime. 
In the SS group, AS100 showed fewer 
symptoms all the other concentrations (all p < 
0.01) and was associated with decreased corneal 
staining at 12-week post-treatment (p = 0.041).  
 
 
Topical immunosuppressive therapy 
Hong et al, 
2007 (23).  
Prospective trial, 53 SS patients 
treated with methylprednisolone, 4 
times daily for the first two weeks, 
tapered off every 2 weeks.  
Significantly improved tear break-up time 
(BUT) and Schirmer test results at the end 
of the treatment period and drug-free 
remission for a duration of 56.6 weeks and 
20.8% recurrences. After the second pulse-
therapy the drug-free remission period was 
72.4 weeks. 
Devecı et al, 
2014 (52).  
Prospective study,  
26 SS patients treated for 1 month with 
cyclosporine A 0.05 % topical, vs. 20 SS 
patients treated with saline solution. 
Improvement in subjective symptoms (burning-
prickling sensation, light sensitivity, pain) and 
redness (p=0.0001) at 1 month. 
Improvement of the Shirmer test (p=0.0001) 
and tear BUT (p = 0.0001) at 1 month.  
Sall et al, 2000 
(32).  
RCT, 24 weeks, topical cyclosporine 
0.05% (n=293) and 0.1% (n=292) vs. 
placebo (n=292). 
0.05% vs. placebo: better corneal staining score 
(p =0.008), Schirmer test score (p<0.007), better 
score for blurred vision (p<0.01), and decrease 
in concomitant use of artificial tears (p<.006). 
 
Cyclosporine 0.1% group had a better corneal 
staining score (p<0.06), Schirmer test (p 
<0.007) than the placebo group. 
Kim et al, 2009 
(33).  
RCT, 12 weeks, topical cyclosporine 
0.05% (n=50) vs. vitamin A (n=50) vs.  
carboxymethylcellulose (CMC)  (n=50). 
Improvement of reported blurred vision 
(cyclosporine and vitamin A vs. CMC, p<0.05), 
better break-up time (BUT) (cyclosporine and 
vitamin A vs. CMC, p<0.05), better Schirmer 
test score (cyclosporine and vit A vs. CMC, 
p<0.05). 
Roberts et al, 
2007 (29).  
RCT, 6 months, topical cyclosporine 
0.05% (n=10) vs. cyclosporine 0.05% + 
punctal occlusion (PO) (n=10), PO only 
(n=10).  
Cyclosporine and cyclosporine/PO groups vs. 
PO only group had no significant improvement 
in the Schirmer test score (3.0 and 3.9 vs. 3.8), 
but patient used less artificial tears in the 
cyclosporine/PO vs. PO groups (−3.9 vs. −2.1; 
p=0.01) 
Dastjerdi et al, 
2009 (31). 
Retrospective study, cohort of 22 patients 
(13 patients with ocular graft versus host 
disease and 9 patients with SS) treated 
with cyclosporine 0.05% 
After a minimum of a 2-month course of 
treatment with a frequent dosing of cyclosporine 
0.05%, overall dry eye symptoms were 
improved in 15 (68.2%) patients (9 patients with 
ocular graft versus host disease and 6 patients 
with SS). 
Oral muscarinic agonists 
Tsifetaki et al, 
2013 (35).  
A 12 week RCT, n=85, oral pilocarpine 5 
mg twice a day (n=29) vs. artificial tears 
(n=28) vs. inferior puncta occlusion 
(n=28). Patients receiving oral pilocarpine 
and those with inferior puncta occlusion 
also received artificial tears.  
Pilocarpine was more effective than artificial 
tears (p<0.001) and inferior puncta occlusion 
(p<0.05) in improving the subjective symptoms 
dry eyes as assessed using a VAS. Pilocarpine 
also was associated with more significant 
objective improvement of symptoms of dry eye, 
as measured by the Rose Bengal test (p<0.05), 
while Schirmer’s-I test showed no differences 
between the treated groups. 
Papas et al, 
2004 (36).  
12 week RCT (n=256 patients), placebo-
controlled, dose-adjustment study, oral 
pilocarpine (n=128) 20 mg to 30 mg daily 
vs. placebo (n=128). 
The pilocarpine group demonstrated both 
significant improvement in global assessment of 
dry eyes (p 0.0001) and dry eye relief as 
assessed by improvement of in 6 of 8 related 
symptoms (p≤0.04). 
Vivino et al, 
1999 (37).  
RCT, double blind, 12 weeks, oral 
pilocarpine 2.5 mg/6h (n=121) and 5 mg/6 
h (n=127) vs. placebo (n=125).  
Primary outcomes met: improvement of dry 
mouth symptoms (5 mgx4/ daily vs. placebo) in 
61% vs. 31% SS patients (p<.001), and dry eyes 
symptoms in 42% vs. 26%, (p=0.009);  
Conventional DMARDs 
Rihl et al, 2009 
(40) . 
Retrospective analysis of 14 patients with 
pSS with vs. 21 patients with objective 
sicca symptoms were treated with HCQ 
for up to 6 months. 
The sicca group showed a significant increase in 
tear production (p=0.001). There was a positive 
correlation between the α-fodrin IgA antibody 
titer and the Schirmer’s test at baseline (r=0.66; 
p=0.001) and after treatment (r=0.6; p=0.004) in 
this group.   
Gottenberg et RCT, n=120 SS patients receiving HCQ Between weeks 0 and 24, the mean (SD) 
al., 2014 (42) 400 mg daily vs. placebo for 24 weeks and 
active medication from week 24 to 48. 
numeric analogue scale score for dryness 
changed from 6.38 (2.14) to 5.85 (2.57) in the 
placebo group and 6.53 (1.97) to 6.22 (1.87) in 
the HCQ group (p=0.55) 
Van Woerkom 
et al, 2007 
(44). 
Pilot study, 15 patients with early and 
active pSS received Leflunomide 20mg 
once daily for 24 weeks.  
Schirmer test values didn't reach statistical 
significance. No changes were observed in the 
reported perceived ocular dryness. 
Biologic treatments 
Sankar et al, 
2004 (53).  
RCT, double-blind, 12 weeks, etanercept 
25 mg (n=14) twice per week vs. placebo 
(n=14). 
None of the primary and secondary outcomes 
were met at week 12. 
There was no statistical significant difference 
between the treated and placebo groups as far as 
the ocular dryness VAS (p=0.53) and Schirmer 
test (p=0.55), were concerned. 
Meijer et al, 
2010 (54).  
48 week, randomized, double-blind, 
placebo-controlled trial, rituximab (RTX) 
1 g. twice at day 1 and 15 (n=20) vs. 
placebo (n=10).  
The lissamine green test showed significant 
improvement in lacrimal gland function in the 
rituximab group from baseline to weeks 5–48. 
However the Schirmer’s test and BUT test 
revealed no significant changes in lacrimal 
gland function in either group. 
Carubbi et al, 
2013 (55).  
120 week, prospective, follow-up study, 
n=41 patients with early pSS and active 
disease, RTX 1 g/15 d (n=19) vs. 
DMARDs (n=22). 
 RTX treatment resulted in a faster and more 
pronounced decrease of ESSDAI (p<0.001) 
from week 24. Both the unstimulated salivary 
flow and the Schirmer’s I test were significantly 
increased in the RTX group from week 12 
(p<0.001). 
Devauchelle-
Pensec et al, 
2014 (56) 
24 week RCT including 120 patients with 
scores of 50 mm or greater on at least 2 of 
4 VASs (global disease, pain, fatigue, and 
dryness) and recent-onset (< 10 years) 
biologically active or systemic pSS treated 
with RTX (1 g twice) vs. placebo. 
The proportion of patients with at least 30-mm 
decreases in at least two of the four VAS scores 
(assessing global disease, pain, fatigue, and 
dryness),  was higher in the RTX group at week 
6 (22.4% vs. 9.1%; P = 0.036) 
Meiners et al, 
2014 
(57) 
48 week RCT, n=28 patients with SS, 
weekly subcutaneous administration of 
125 mg abatacept. 
Significant improvement in the lissamine green 
test from baseline to weeks 5–48 in the 
abatacept group. However the Schirmer’s and 
BUT tests did not change significantly in any of 
the groups 
Steinfeld et al. 
(58) 
6 months RCT, 4 i.v. infusions 
epratuzumab administered every two 
weeks vs. placebo 
Fifty-three percent achieved a clinical response 
(improvement of at least 20% of a composite 
score including 5 parameters, which one of 
them being the Schirmer’s tests) at 6 weeks, 
with 53%, 47%, and 67% responding at 10, 18, 
and 32 weeks, respectively. 
Marriette et al., 
2013 
(59) 
52 week open label trial, 103 patients with 
SS, 10 mg/kg belimumab i.v., monthly. 
Improvement of the dryness as assessed by 
VAS from 7.8 (1.8) to 6.2 (2.9) (p=0.0021). No 
improvement in the Schirmer test at 6 months.  
 
 
 
Biologic treatments 
Increased interest in testing biologic therapies effect in SS patients is evident (60). 
Etanercept, a TNF receptor fusion protein licensed for use in rheumatoid arthritis and 
ankylosing spondylitis, was tested for efficacy in a 12-week, double blind RCT (53). None of 
the study outcomes were met as patients did not improve after 12 weeks of treatment. The 
negative results included objective and subjective assessment of ocular dryness (p=0.53 and 
p=0.55, respectively) (53).  
The most encouraging results related to the use of biologic treatment in SS to address the 
symptoms of ocular dryness came from two RCT with rituximab (RTX). In a 48 week RCT of 
RTX vs. placebo, the lacrimal gland function assessed by the lissamine green test showed 
significant improvement in the rituximab group from baseline to weeks 5–48. However the 
Schirmer’s and BUT tests did not change significantly in any of the groups (54) .  
 
A prospective study which enrolled 41 patients with early pSS and active disease and 
followed for up to 120 weeks, demonstrated that RTX treatment results in a faster and more 
pronounced decrease of ESSDAI (p<0.001) from week 24. RTX treatment significantly 
increased the Schirmer tests from week 12 (p<0.001) (55).  
 
A recently published RCT with RTX vs. placebo in patients with recent-onset or systemic pSS  
reported negative results as it did not reach the primary outcome, improvement of at least 
30 mm in 2 of 4 VASs by week 24. However, there was a signal of efficacy of RTX at earlier 
time points as the proportion of patients with at least 30-mm decreases in at least two of 
the four VAS scores was higher in the RTX group at week 6 (22.4% vs. 9.1%; P = 0.036). (56).  
 
There is only one open label pilot study of abatacept in pSS (n=15), which reported no 
improvement in the salivary and lacrimal function, despite the encouraging results 
suggesting improved disease activity, laboratory parameters, fatigue and HR-QoL at weeks 
24 and 44 (57). 
 
An open-label, phase I/II study investigated the safety and efficacy of epratuzumab, a 
humanised anti-CD22 monoclonal antibody, in the treatment of 16 patients with active pSS 
(58). The response to the treatment was assessed using a composite endpoint, including the 
Schirmer test. Fifty-three percent achieved a clinical response (at > or = 20% improvement 
level) evaluated by this composite endpoint at 6 weeks, with 53%, 47%, and 67% responding 
at 10, 18, and 32 weeks, respectively (58). 
 
Another B cell targeted therapy, belimumab, which is a monoclonal antibody that inhibits B-
cell activating factor (BAFF) was tested in patients with SS in a prospective 1-year open-label 
trial (59). The primary end-point was defined as improvement in two of five items: reduction 
in ≥30% in dryness score on a visual analogue scale (VAS), ≥30% in fatigue VAS score, ≥30% 
in VAS pain score, ≥30% in systemic activity VAS assessed by the physician and/or >25% 
improvement in any B cell activation biomarker values. The primary end-point was achieved 
in 18 (60%). The mean dryness assessed by VAS varied from 7.8 (1.8) to 6.2 (2.9) (p=0.0021) 
but the Schirmer test didn’t improve significantly after 6 months (59).  
 
New biologic targets have emerged from in vivo and animal studies, such as Fas and CD 40 
involved in the epithelial apoptosis associated with SS, which could represent the therapies 
of the future (61). 
 
A proposed algorithm:  
Based on the available evidence from the literature data and the current recommendations 
for the management of dry eye symptoms (62), we propose a following algorithm (Figure 1) 
of ocular dryness treatment in patients with SS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First line therapy 
Education  
Environmental and offending medication 
modification 
Level of evidence III 
Topical lubricants 
(Preserved artificial tear substitutes, gels and 
ointments) 
Level of evidence I a 
If not effective 
Second line therapy 
Topical lubricants 
Non-preserved artificial tear 
substitutes, followed by autologous 
serum or umbilical cord serum. 
 Level of evidence Ia 
Short-term topical 
immunomodulatory agents  
Corticosteroids (level of evidence 
IIa) 
Cyclosporine - not licensed in the 
UK (level of evidence Ia) 
 
Secretagogues 
Pilocarpine and Cevimeline 
 
Level of evidence Ia 
 
If not effective 
B cell target therapy  
(not licensed) 
Rituximab - level of evidence Ia 
Belimumab – level of evidence Ib 
Epratuzumab – level of evidence Ib 
 
Punctal plugs, followed by 
permanent punctal occlusion 
 Level of evidence Ia 
Co-stimulatory inhibition  
(not licensed) 
Abatacept – level of evidence Ib 
  
 
 
 
 
 
 
Fig 1. A proposed algorithm for the treatment of dry eye associated with SS 
 
 
 
Conclusions:  
Despite being one of the central symptoms of SS, associated with significant impact of the 
quality of life of these patients, the ocular dryness is usually managed with tear substitution 
or topical anti-inflammatory/immunomodulatory medication. There is no good evidence for 
the efficacy of conventional DMARDs in improving lacrimal gland secretion in SS patients, 
apart from methotrexate, which only improved the subjective symptoms of ocular dryness 
in a small study and hydroxychroloquine, which improved the tear secretion in small, non 
RCT studies. A recent RCT proved no efficacy of this treatment as assessed at week 24. In 
comparison, there is good evidence that both pilocarpin and cevimeline are useful in 
improving the ocular dryness in patients with SS.  Interesting and exciting results have been 
provided by the RCT involving new biologic therapies, which have shown improvement in 
many of the patient reported outcome measures related to symptoms of dryness. There is 
also evidence, from a prospective study, that rituximab improved the lacrimal secretion and 
histologic scores as well. Epratuzumab also improved a composite score, including the 
Schirmer test, in an open label, early phase study. It was emphasized from previous studies, 
that the selection of patients with early disease and residual lacrimal and salivary function is 
pivotal in ensuring a functional response following treatment.  
 
If not effective 
Rescue therapy 
Corneal transplant 
Level of evidence IV 
 
Stem cell allografts 
Level of evidence IV 
 
In conclusion, the therapeutic armamentarium available for the treatment of ocular dryness 
associated with SS has expanded significantly in the last decade, as new biologic therapies 
targeting specific cells and molecules in patients with early disease have emerged.  Apart 
from the biologic treatments, no systemic therapies are effective in SS. The dry eye 
treatment approach in SS differs from the treatment of other symptoms associated with SS, 
proving that patients benefit from an interdisciplinary approach and ophthalmological 
periodic review.  
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